+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatitis D - Pipeline Review, H2 2019

  • ID: 4894220
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 92 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • CN Bio Innovations Ltd
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Hepion Pharmaceuticals
  • Merck & Co Inc
  • MYR GmbH
  • MORE
Hepatitis D - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H2 2019, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • CN Bio Innovations Ltd
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Hepion Pharmaceuticals
  • Merck & Co Inc
  • MYR GmbH
  • MORE
Introduction
Report Coverage
Hepatitis D - Overview
Hepatitis D - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis D - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis D - Companies Involved in Therapeutics Development
CN Bio Innovations Ltd
Eiger BioPharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Globeimmune Inc
Hepion Pharmaceuticals
Merck & Co Inc
MYR GmbH
PharmaEssentia Corp
Replicor Inc
Rodos BioTarget GmbH
SomaGenics Inc
Hepatitis D - Drug Profiles
Antisense RNAi Oligonucleotide for Hepatitis D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bulevirtide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRV-431 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GI-18000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lonafarnib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon lambda-1a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBT-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REP-2139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REP-2165 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Hepatitis D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Hepatitis B and Hepatitis D Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vanitaracin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis D - Dormant Projects
Hepatitis D - Product Development Milestones
Featured News & Press Releases
Nov 12, 2019: Eiger announces Peginterferon Lambda - Lonafarnib combination interim results in Hepatitis Delta Virus (HDV) infection from phase 2 LIFT study during late-breaker oral presentation at AASLD 2019
Nov 01, 2019: MYR Pharmaceuticals announces multiple presentations at the AASLD Meeting 2019 in Boston
Oct 21, 2019: Eiger announces Peginterferon Lambda combination therapy for treatment of chronic hepatitis delta virus (HDV) infection to be featured in a late-breaking oral presentation at AASLD 2019
Aug 20, 2019: Eiger announces FDA breakthrough therapy designation for Peginterferon Lambda for treatment of hepatitis delta virus infection
Jul 29, 2019: Replicor announces publication of new study examining HBsAg evolution during REP 2139
Jun 10, 2019: Replicor presents final REP 401 data demonstrating persistent functional cure of HBV
May 17, 2019: Eiger BioPharmaceuticals announces transition of Chief Operating Officer and Executive Medical Officer
Apr 11, 2019: Eiger Announces 36% durable virologic response at 24 weeks post-treatment with peginterferon lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
Apr 04, 2019: MYR Pharmaceuticals announces presentation of final results of the MYR203 study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna
Apr 01, 2019: Replicor to present latest data on the beneficial impact of transaminase flares in achieving HBV functional cure at the 2019 EASL ILC meeting
Mar 26, 2019: Eiger BioPharmaceuticals to Participate in Conferences in April 2019
Mar 26, 2019: Eiger BioPharmaceuticals to participate in conferences
Mar 13, 2019: Eiger late-breaker oral presentation of peginterferon lambda Phase 2 LIMT study at The International Liver Congress 2019
Mar 05, 2019: MYR Pharma announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the first-in-class entry inhibitor for treatment of chronic hepatitis d infections
Feb 06, 2019: Eiger Biopharmaceuticals announces patent protection for Lonafarnib boosted with Ritonavir for treatment of hepatitis delta virus infection in Europe and Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hepatitis D, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hepatitis D - Pipeline by CN Bio Innovations Ltd, H2 2019
Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, H2 2019
Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Hepatitis D - Pipeline by Globeimmune Inc, H2 2019
Hepatitis D - Pipeline by Hepion Pharmaceuticals, H2 2019
Hepatitis D - Pipeline by Merck & Co Inc, H2 2019
Hepatitis D - Pipeline by MYR GmbH, H2 2019
Hepatitis D - Pipeline by PharmaEssentia Corp, H2 2019
Hepatitis D - Pipeline by Replicor Inc, H2 2019
Hepatitis D - Pipeline by Rodos BioTarget GmbH, H2 2019
Hepatitis D - Pipeline by SomaGenics Inc, H2 2019
Hepatitis D - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Hepatitis D, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • CN Bio Innovations Ltd
  • Eiger BioPharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Hepion Pharmaceuticals
  • Merck & Co Inc
  • MYR GmbH
  • PharmaEssentia Corp
  • Replicor Inc
  • Rodos BioTarget GmbH
  • SomaGenics Inc
Note: Product cover images may vary from those shown
Adroll
adroll